The dramatic rise of antibiotic-resistant bacteria over the past two decades has stressed the need for completelynovel classes of antibacterial agents. Accordingly, recent advances in the study of prokaryotic transcriptionopen new opportunities for such molecules. This paper reports the structure-activity relationships of aseries of phenyl-furanyl-rhodanines (PFRs) as antibacterial inhibitors of RNA polymerase (RNAP). Themolecules have been evaluated for their ability to inhibit transcription and affect growth of bacteria livingin suspension or in a biofilm and for their propensity to interact with serum albumin, a critical parameterfor antibacterial drug discovery. The most active of these molecules inhibit
Escherichia coli RNAPtranscription at concentrations of
![](/images/entities/le.gif)
10
![](/images/entities/mgr.gif)
M and have promising activities against various Gram-positivepathogens including
Staphylococcus epidermidis biofilms, a major cause of nosocomial infection.